India’s leadning pharma major Torrent Pharmaceuticals Ltd is looking for the possible acquisition of the domestic business of Unichem Laboratories.
Similar acquisition is made by Torrent Pharma. Torrent Pharma had acquired Elder’s domestic business and that in Nepal for over Rs. 2,000 crore.
Inorganic growth opportunities play an important part of Torrent Pharma’s growth strategy besides product innovation and market expansion. Unichem’s rich portfolio of cardiovascular drugs, including Losar, is expected to add to Torrent Pharma’s existing offering.
For the fiscal 2016-17, Unichem had reported a net profit of Rs. 103.87 crore on revenues of Rs. 1,413.85 crore with earnings per share of Rs. 11.29.
Torrent Pharma recently involved in lot of acquisitions. In 2015-16, the company had acquired Zyg Pharma – USFDA approved dermatology platform and also acquired Minocycline ANDA for the US market from Sun Pharmaceuticals.